EGFR and lung cancer: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is an effective therapy for epidermal growth factor receptor–mutated non–small cell lung cancer, but it has been associated with a higher incidence of cardiotoxicity.